Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 103-109

  Borovcanin, Milica ^a   Jovanovic, Ivan ^a   Radosavljevic, Gordana ^a   Djukic Dejanovic, Slavica ^a   Stefanovic, Vesna ^b   Arsenijevic, Nebojsa ^a   Lukic, Miodrag L ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b Clinic for Psychiatric Disorders 'Dr Laza Lazarevi '   (Serbia)

Author keywords

Antipsychotics; IL 17; IL 27; IL 4; Schizophrenia; TGF

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84877102986     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.027     Document Type: Article

References (52)

1. Abbas A., Lichtman A.H., Pillai S. Cellular and Molecular Immunology 2007, Saunders, Elsevier, Philadelphia, USA. 6th edition.
2. Avgustin B., Wraber B., Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat. Med. J. 2005, 46(2):268-274.
3. Bechter K. The mild encephalitis-hypothesis-new findings and studies. Psychiatr. Prax. 2004, 31(Suppl. 1):S41-S43.
4. Borovcanin M., Jovanovic I., Radosavljevic G., Djukic Dejanovic S., Bankovic D., Arsenijevic N., Lukic M.L. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J. Psychiatr. Res. 2012, 46(11):1421-1426.
5. Carpenter W.T. The facts of schizophrenia: a personal commentary. Schizophr. Res. 2011, 128(1-3):3-4.
6. Cazzullo C.L., Trabattoni D., Saresella M., Annoni G., Arosio B., Clerici M. Research on psychoimmunology. World J. Biol. Psychiatry 2003, 4(3):119-123.
7. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349:1738-1749.
8. Gabay C., McInnes I.B. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res. Ther. 2009, 11(3):230.
9. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 2005, 6:7.
10. Himmerich H., Schönherr J., Fulda S., Sheldrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. J. Psychiatr. Res. 2011, 45(10):1358-1365.
11. Hinze-Selch D., Becker E.W., Stein G.M., Berg P.A., Mullington J., Holsboer F., Pollmächer T. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998, 19(2):114-122.
12. Kalkman H.O. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol. Ther. 2009, 121(1):115-122.
13. Kallmann B.A., Hüther M., Tubes M., Feldkamp J., Bertrams J., Gries F.A., Lampeter E.F., Kolb H. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997, 46(2):237-243.
14. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 2007, 92(1-3):108-115.
15. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., Iwaki T., Hashioka S., Kanba S. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem. 2008, 106(2):815-825.
16. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale Manual 1994, Multi-Health Systems, North Tonawanda, NY.
17. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(7):1129-1134.
18. Koyasu S., Moro K. Type 2 innate immune responses and the natural helper cell. Immunology 2011, 132(4):475-481.
19. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157(5):683-694.
20. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011, 33(3):268-274.
21. Labuzek K., Kowalski J., Gabryel B., Herman Z.S. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur. Neuropsychopharmacol. 2005, 15(1):23-30.
22. Leykin I., Mayer R., Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997, 37(1):75-86.
23. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpé S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32(1):9-15.
24. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 1994, 89(5):346-351.
25. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29(2):141-152.
26. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 1997, 26(2-3):221-225.
27. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav. Immun. 2011, 25(8):1507-1518.
28. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
29. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63:257-265.
30. Müller N., Schwarz M.J. Immune system and schizophrenia. Curr. Immunol. Rev. 2010, 6(3):213-220.
31. Müller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247(6):308-313.
32. Müller N., Riedel M., Ackenheil M., Schwarz M.J. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J. Biol. Psychiatry 2000, 1(4):173-179.
33. Müller N., Riedel M., Gruber R., Manfred A., Schwarz M. The immune system and schizophrenia-an integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
34. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 2008, 160(3):256-262.
35. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., Lee S.J., Lee C., Paik I.H. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int. Immunopharmacol. 2006, 6(4):666-671.
36. Pedersen M.S., Benros M.E., Agerbo E., Børglum A.D., Mortensen P.B. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr. Res. 2012, 138(1):58-62.
37. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996, 16(5):403-409.
38. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
39. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., Di Nicola M., Grilli A. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 2011, 12:13.
40. Schmitt A., Bertsch T., Tost H., Bergmann A., Henning U., Klimke A., Falkai P. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr. Dis. Treat. 2005, 1(2):171-177.
41. Shen W.W. A history of antipsychotic drug development. Compr. Psychiatry 1999, 40(6):407-414.
42. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47(1):1-5.
43. Song C., Lin A., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 2000, 42(2):157-164.
44. Vawter M.P., Dillon-Carter O., Issa F., Wyatt R.J., Freed W.J. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology 1997, 16(1):83-87.
45. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010, 64(3):217-230.
46. World Health Organization International Statistical Classification of Diseases and Related Health Problems, Tenth Revision 1992, World Health Organization, Geneva.
47. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010, (832454. Published online 2010 September 14). 10.1155/2010/832454.
48. Yilmaz Z., Zai C.C., Hwang R., Mann S., Arenovich T., Remington G., Daskalakis Z.J. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr. Res. 2012, 140(1-3):214-220.
49. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8(1):131-145.
50. Yoshida H., Nakaya M., Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J. Leukoc. Biol. 2009, 86(6):1295-1303.
51. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30(8):1532-1538.
52. Zheng L.T., Hwang J., Ock J., Lee M.G., Lee W.H., Suk K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J. Neurochem. 2008, 107(5):1225-1235.